Nutritional pharmacology and malignant disease: A therapeutic modality in patients with cancer

British Journal of Surgery

Volumn 83, Issue 5, 1996, Pages 608-619

  Heys, S D ^a   Gough, D B ^a   Khan, L ^a   Eremin, O ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ESSENTIAL FATTY ACID; GLUTAMINE; POLYRIBONUCLEOTIDE;

CACHEXIA; CANCER; CELL GROWTH; CELL METABOLISM; HOST RESISTANCE; HUMAN; INFECTION; NITROGEN METABOLISM; NUTRITION; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; WOUND HEALING;

ANIMALS; ARGININE; CELL DIVISION; FATTY ACIDS, ESSENTIAL; GLUTAMINE; HUMANS; IMMUNITY; NEOPLASMS; NITROGEN; POLYRIBONUCLEOTIDES; WOUND HEALING;

EID: 0029954035     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830508     Document Type: Review

References (135)

1. Rose WC. The amino acid requirements of adult man. Nutrition Abstract Review 1957; 27: 631-47.
2. Nakagawa J, Takahashi T, Suzuki T, Kobayashi K. Amino acid requirements of children: minimal needs of tryptophan, arginine, histidine based on nitrogen balance method. J Nutr 1963; 80: 305-10.
3. Kirk SJ, Barbul A. Role of arginine in trauma, sepsis and immunity. JPEN J Parenter Enteral Nutr 1990; 14(5 Suppl): 226-9S.
4. Rogers QR, Freedland RA, Symmons RA. In vivo synthesis and utilization of arginine in the rat. Am J Physiol 1972; 223: 236-40.
5. Visek WJ. Arginine needs, physiological state and usual diets. A reevaluation. J Nutr 1986; 116: 36-44.
6. Walser M. Urea cycle disorders and other hereditary disorders in hyperammonemic syndromes. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1978: 402-38.
7. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; C212-21.
8. Moncada S, Palmer RMJ, Higgs EA. Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol 1989; 38: 1709-15.
9. Marietta MA, Tayeh MA, Hevel JM. Unraveling the biological significance of nitric oxide. Biofactors 1990; 2: 219-25.
10. Seifter E, Rettura G, Barbul A, Levenson SM. Arginine: an essential amino acid for injured rats. Surgery 1978; 84: 224-30.
11. Sitren HS, Fisher H. Nitrogen retention in rats fed on diets enriched with arginine and glycine. I. Improved N retention after trauma. Br J Nutr 1977; 37: 195-208.
12. Elsair J, Poey J, Isaad J et al. Effect of arginine chlorohydrate on nitrogen balance during the three days following surgery in man. Biomedicine 1978; 29: 312-17.
13. Daly JM, Reynolds J, Thom A et al. Immune and metabolic effects of arginine in the surgical patient. Ann Surg 1988; 208: 512-23.
14. Barbul A, Lazarou SA, Efron DT, Wasserkrug HL, Efron G. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 1990; 108: 331-7.
15. Park KGM, Heys SD, Blessing K et al. Stimulation of human breast cancers by dietary L-arginine. Clin Sci 1992; 82: 413-17.
16. Brittenden J, Heys SD, Miller I et al. Dietary supplementation with L-arginine in patients with breast cancer (> 4 cm) receiving multimodality treatment: report of a feasibility study. Br J Cancer 1994; 69: 918-21.
17. Nirgiotis JG, Hennessey PJ, Andrassy RJ. The effects of an arginine-free enteral diet on wound healing and immune function in the postsurgical rat. J Pediatr Surg 1991; 26: 936-41.
18. Barbul A, Rettura G, Levenson SM, Seifter E. Arginine: a thymotropic and wound-healing promoting agent. Surgical Forum 1977; 28: 101-3.
19. Barbul A, Rettura G, Levenson SM, Seifter E. Wound healing and thymotropic effects of arginine: a pituitary mechanism of action. Am J Clin Nutr 1983; 37: 786-94.
20. Zinker S, Rojkind M. Collagen biosynthesis in the chick embryo. I. The source of free proline and collagen hydroxyproline. Connect Tissue Res 1972; 1: 275-81.
21. Barbul A, Wasserkrug HL, Sisto DA et al. Thymic stimulatory actions of arginine. JPEN J Parenter Enteral Nutr 1980; 4: 446-9.
22. Reynolds JV, Zhang SM, Thom AK, Zeigler MM, Naji A, Daly JM. Arginine as an immunomodulator. Surgical Forum 1987; 38: 415-18.
23. Barbul A, Sisto DA, Wasserkrug HL, Efron G. Arginine stimulates lymphocyte immune response in healthy human beings. Surgery 1981; 90: 244-51.
24. Eremin O. Cancer and the immune response. In: Eremin O, Sewell H, eds. The Immunological Basis of Surgical Science and Practice. Oxford: Oxford University Press, 1992: 87-102.
25. Reynolds JV, Daly JM, Shou J, Sigal R, Ziegler MM, Naji A. Immunologic effects of arginine supplementation in tumor-bearing and non-tumor-bearing hosts. Ann Surg 1989; 211: 202-10.
26. Lieberman MD, Nishioka K, Redmond HP, Daly JM. Enhancement of interleukin-2 immunotherapy with L-arginine. Ann Surg 1992; 215: 157-65.
27. Park KGM, Hayes PD, Garlick PJ, Sewell H, Eremin O. Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet 1991; 337: 645-6.
28. Brittenden J, Park KGM, Heys SD et al. L-Arginine stimulates host defenses in patients with breast cancer. Surgery 1994; 115: 205-12.
29. Brittenden J, Heys SD, Ross J, Park KGM, Eremin O. Natural cytotoxicity in breast cancer patients receiving neoadjuvant chemotherapy: effects of L-arginine supplementation. Eur J Surg Oncol 1994; 20: 467-72.
30. Bruce DM, Heys SD, Segar A, Payne S, Kernohan NM, Eremin O. Enhancement of tumour-infiltrating lymphocytes in human tumours by dietary supplementation with L-arginine. Br J Surg 1995; 82: 703 (Abstract).
31. Hibbs JB Jr, Vavrin Z, Taintor RR. L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987; 138: 550-65.
32. Albina JE, Caldwell MD, Henry WL Jr, Mills CD. Regulation of macrophage functions by L-arginine. J Exp Med 1989; 169: 1021-9.
33. Moriguchi S, Mukai M, Hiraoka J, Kishino Y. Functional changes in human lymphocytes and monocytes after in vitro incubation with arginine. Nutrition Research 1987; 7: 719-29.
34. Brittenden J, Heys SD, Ross J, Park KGM, Eremin O. Nutritional pharmacology: effects of L-arginine on host defences, response to trauma and tumour growth. Clin Sci 1994; 86: 123-32.
35. Cho-Chung YS, Clair T, Bodwin JS, Berghoffer B. Growth arrest and morphological change of human breast cancer cells by dibutyryl cyclic AMP and L-arginine. Science 1981; 214: 77-9.
36. Park KGM, Heys SD, Eremin O, Garlick PJ. The effect of L-arginine on the growth and metabolism of an experimental lung cancer. J Cancer Res Clin Oncol 1990; 116(Suppl 1): 247 (Abstract).
37. Levy HM, Montañez G, Feaver ER, Murphy EA, Dunn MS. Effect of arginine on tumor growth in rats. Cancer Res 1954; 14: 198-200.
38. Reynolds JV, Thom AK, Zhang SM, Ziegler MM, Naji A, Daly JM. Arginine, protein malnutrition, and cancer. J Surg Res 1988; 45: 513-22.
39. Beard HH. The effect of subcutaneous injection of individual amino acids upon the appearance, growth, and disappearance of Emge sarcoma in rats. Experimental Medicine and Surgery 1943; 1: 123-35.
40. Takeda Y, Tominaga T, Tei N, Kitamura M, Taga S. Inhibitory effect of L-arginine on growth of rat mammary tumors induced by 7,12 dimethylbenz(a)anthracene. Cancer Res 1975; 35: 2390-3.
41. Yeatman TJ, Risley GL, Brunson ME. Depletion of dietary arginine inhibits growth of metastatic tumor. Arch Surg 1991; 126: 1376-82.
42. Remvikos Y, Beuzeboc A, Zajdela A, Voillemot N, Magdelenat H, Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989; 81: 1383-7.
43. Heys SD, Sarkar TK, Ah-See AK, Eremin JM, Bittenden J, Eremin O. Multimodality treatment in the management of locally advanced breast cancer. J R Coll Surg Edinb 1993; 38: 9-15.
44. Häussinger D, Sies H. Glutamine Metabolism in Mammalian Tissues. Berlin: Springer, 1984.
45. Bergstrom J, Furst P, Noree L-O, Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol 1974; 36: 693-6.
46. Salzman NP, Eagle H, Sebring ED. The utilization of glutamine, glutamic acid, and ammonia for the biosynthesis of nucleic acid bases in mammalian cell cultures. J Biol Chem 1958; 230: 1001-12.
47. MacLennan PA, Brown RA, Rennie MJ. A positive relationship between protein synthetic rate and intracellular glutamine concentration in perfused rat skeletal muscle. FEBS Lett 1987; 215: 187-91.
48. Hartmann F, Plauth M. Intestinal glutamine metabolism. Metabolism 1989; 38(Suppl 1): 18-24.
49. Wellbourne TC. Interorgan glutamine flow in metabolic acidosis. Am J Physiol 1987; 253: F1069-76.
50. Ardawi MSM. Glutamine and glucose metabolism in human peripheral lymphocytes. Metabolism 1988; 37: 99-103.
51. Caldwell MD. Local glutamine metabolism in wounds and inflammation. Metabolism 1989; 38(Suppl 1): 34-9.
52. Clowes GH Jr, Randall HT, Cha C-J. Amino acid and energy metabolism in septic and traumatized patients. JPEN J Parenter Enteral Nutr 1980; 4: 195-205.
53. Aulick LH, Wilmore DW. Increased peripheral amino acid release following burn injury. Surgery 1979; 85: 560-5.
54. Vinnars E, Bergstrom J, Furst P. Influence of the postoperative state on the intracellular free amino acids in human muscle tissue. Ann Surg 1975; 182: 665-71.
55. Parry-Billings M, Evans J, Calder PC, Newsholme EA. Does glutamine contribute to immunosuppression after major burns? Lancet 1990; 336: 523-5.
56. Roth E, Furnovics J, Mühlbacher F et al. Metabolic disorders in severe abdominal sepsis: glutamine deficiency in skeletal muscle. Clinical Nutrition 1982; 1: 25-41.
57. Wernerman J, Hammarqvist F, von der Decken A, Vinnars E. Ornithine-alpha-ketoglutarate improves skeletal muscle protein synthesis as assessed by ribosome analysis and nitrogen balance use after surgery. Ann Surg 1987; 206: 674-8.
58. Hammarqvist F, Wernerman J, Ali R, von der Decken A, Vinnars E. Addition of glutamine to total parenteral nutrition after elective abdominal surgery spares free glutamine in muscle, counteracts the fall in muscle protein synthesis, and improves nitrogen balance. Ann Surg 1989; 209: 455-61.
59. Stehle P, Zander J, Mertes N et al. Effect of parenteral glutamine peptide supplements on muscle glutamine loss and nitrogen balance after major surgery. Lancet 1989; i: 231-3.
60. Ziegler TR, Young LS, Benfell K et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 1992; 116: 821-8.
61. O'Riordain MG, Fearon KCH, Ross JA et al. Glutamine-supplemented total patenteral nutrition enhances T-lymphocyte response in surgical patients undergoing colorectal resection. Ann Surg 1994; 220: 212-21.
62. Tannock IF, Steele D, Roberts J. Influence of reduced concentration of L-glutamine on growth and viability of cells in monolayer, in spheroids, and in experimental tumours. Br J Cancer 1986; 54: 733-41.
63. Viallard V, Denis C, Trocheris V, Murat JC. Effect of glutamine deprivation and glutamate or ammonium chloride addition on growth rate, metabolism and differentiation of human colon cancer cell-line HT29. Int J Biochem 1986; 18: 263-9.
64. Ollenschlager G, Simmel A, Roth E. Availability of glutamine from peptides and acetylglutamine for human tumor-cell cultures. Metabolism 1989; 38(Suppl 1): 40-2.
65. Weber G, Lui MS, Seboldt J, Faderan MA. Molecular targets of anti-glutamine therapy with acivicin in cancer cells. In: Häussinger D, Sies H, eds. Glutamine Metabolism in Mammalian Tissues. Berlin: Springer, 1984: 278-91.
66. Chance WT, Cao L, Kim MW, Nelson JL, Fischer JE. Reduction of tumor growth following treatment with a glutamine antimetabolite. Life Sci 1988; 42: 87-94.
67. Chance WT, Cao L, Zhang F-S, Fischer JE. Clenbuterol plus acivicin decrease tumor growth and increase muscle mass in rats maintained on total parenteral nutrition. Am J Surg 1991; 161: 51-6.
68. Horrobin DF, Manku MS. Clinical biochemistry of essential fatty acids. In: Horrobin DF, ed. Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. New York: Wiley-Liss, 1990: 21-53.
69. Manner T, Katz DP, Skeie B, Newsholme E, Kirvelä O, Askanazi J. Fish oils and the lung. Clinical Nutrition 1993; 12: 131-46.
70. Mitsuhashi N, Takano A, Kato J. Inhibition of the binding of R-5020 and rat uterine progesterone receptors by long chain fatty acids. Endocrinol Jpn 1986; 33: 251-6.
71. Cave WT, Erickson-Lucas MJ. Effects of dietary lipids on lactogenic hormone receptor binding in rat mammary tumors. Journal of the National Cancer Institute 1982; 68: 319-24.
72. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983; 3: 295-315.
73. 2. J Immunol 1987; 138: 1074-81.
74. Simopoulos A. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991; 54: 438-63.
75. Goodwin JS, Webb DR. Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol 1980; 15: 106-22.
76. Ertel W, Morrison MH, Ayala A, Chaudry IH. Eicosanoids regulate tumor necrosis factor synthesis after hemorrhage in vitro and in vivo. J Trauma 1991; 31: 609-16.
77. Ertel W, Morrison MH, Ayala A, Perrin MM, Chaudry IH. Blockade of prostaglandin production increases cachectin synthesis and prevents depression of macrophage functions following hemorrhagic shock. Ann Surg 1991; 213: 265-71.
78. Alexander JW, Saito H, Trocki O, Ogle CK. The importance of lipid type in the diet after burn injury. Ann Surg 1986; 204: 1-8.
79. Kelly CJ, Cheung A, Daly JM. Corticosterone and prostaglandin E inhibit perioperative natural killer cell cytotoxicity. Surgical Forum 1993; 44: 482-3.
80. Gottschlich MM, Jenkins M, Warden GD et al. Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN J Parenter Enteral Nutr 1990; 14: 225-36.
81. Gottschlich MM. Selection of optimal lipid sources in enteral and parenteral nutrition. Nutrition In Clinical Practice 1992; 7: 152-65.
82. Calder PC, Newsholme EA. Polyunsaturated fatty acids suppress human peripheral blood lymphocyte proliferation and interleukin-2 production. Clin Sci 1992; 82: 695-700.
83. Meydani SN, Endres S, Woods MM et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 1991; 121: 547-55.
84. Purasiri P, Ashby J, Heys SD, Eremin O. Effect of essential fatty acids on circulating T cell subsets in patients with colorectal cancer. Cancer Immunol Immunother 1994; 39: 217-22.
85. Purasiri P, Ashby J, Heys SD, Eremin O. Effect of essential fatty acids on natural cytotoxicity in patients with colorectal cancer. Eur J Surg Oncol 1995; 21: 254-60.
86. Purasiri P, Murray A, Richardson S, Heys SD, Horrobin D, Eremin O. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci 1994; 87: 711-17.
87. Van der Merwe CF, Booyens J, Katzeff IE. Oral gamma-linolenic acid in 21 patients with untreatable malignancy. An ongoing pilot open clinical trial. Br J Clin Pract 1987; 41: 907-15.
88. Naidu MRC, Das UN, Kishan A. Intratumoral gamma-linolenic acid therapy of human gliomas. Prostaglandins, Leukot Essent Fatty Acids 1992; 45: 181-4.
89. Calder PC, Bond JA, Bevan SJ, Hunt SV, Newsholme EA. Effect of fatty acids on the proliferation of concanavalin A-stimulated rat lymph node lymphocytes. Int J Biochem 1991; 23: 579-88.
90. Anel A, Naval J, Gonzalez B, Uriel J, Pineiro A. Fatty acid metabolism in human lymphocytes. II. Activation of fatty acid desaturase-elongase system during blastic transformation. Biochim Biophys Acta 1990; 1044: 332-9.
91. Nelson KA, Walsh D, Sheehan FA. The cancer anorexiacachexia syndrome. J Clin Oncol 1994; 12: 213-25.
92. Tisdale MJ. Cancer cachexia. Anticancer Drugs 1993; 4: 115-25.
93. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89: 1681-4.
94. Tisdale MJ, Beck SA. Inhibition of tumor-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 1991; 41: 103-7.
95. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford: Clarendon Press, 1985.
96. Cheeseman KH, Burton GW, Ingold KU, Slater TF. Lipid peroxidation and lipid antioxidants in normal and tumor cells. Toxicol Pathol 1984; 12: 235-9.
97. Dormandy TL. An approach to free radicals. Lancet 1983; ii: 1010-14.
98. Cornwell DG, Morisaki N. Fatty acid paradoxes in the control of cell proliferation: prostaglandins, lipid peroxides and cooxidation reactions. In: Pryor WA, ed. Free Radicals in Biology. New York: Academic Press, 1984: 95-148.
99. 2+-induced lipid peroxidation and swelling in the mitochondria isolated from ascites tumor cells. Biochim Biophys Acta 1965; 105: 368-71.
100. Bartoli GM, Galeotti T. Growth-related lipid peroxidation in tumour microsomal membranes and mitochondria. Biochim Biophys Acta 1979; 574: 537-41.
101. Horrobin DF. Essential fatty acids, lipid peroxidation, and cancer. In: Horrobin DF, ed. Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. New York: Wiley-Liss, 1990: 351-77.
102. Lanson M, Bougnoux P, Besson P et al. N-6 polyunsaturated fatty acids in human breast carcinoma: phosphatidyl-ethanolamine and early relapse. Br J Cancer 1990; 61: 776-8.
103. Begin ME, Ells G, Horrobin DF. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst 1988; 80: 188-94.
104. 1 on three human colon carcinoma cell lines. Prostaglandins, Leukot Essent Fatty Acids 1992; 47: 313-19.
105. Begin ME. Tumor cytotoxicity of essential fatty acids. Nutrition 1989; 5: 258-60.
106. McMillan DN, Murray A, Noble BS, Purasiri P, Heys SD, Eremin O. Differential responses of human solid tumour cells in vitro to essential fatty acids. Eur J Surg Oncol 1994; 20: 104-5 (Abstract).
107. Abou-el-Ela SH, Prasse KW, Carroll R, Wade AE, Dharwadkar S, Bunce OR. Eicosanoid synthesis in 7,12-dimethylbenz-(a)-anthracine-induced mammary carcinomas in Sprague-Dawley rats fed primrose oi , menhaden oil or corn oil diet. Lipids 1988; 23: 948-53.
108. McIllmurray M, Turkie W. Controlled trial of gamma-linolenic acid in Dukes C colorectal cancer. BMJ 1987; 294: 1260.
109. McMillan DN, Heys SD, Murray AW et al. Differential responses of human tumour cells to polyunsaturated fatty acids: stimulation of proliferation of a colon tumour cell line by docosahexaenoic acid. International Journal of Oncology 1995; 7: 927-3.
110. Neades GT, Jones DL, Hughes LE. Effect of polyunsaturated fatty acids on doxorubicin sensitivity in MCF-7 cells. Br J Surg 1991; 78: 749 (Abstract).
111. Plumb JA, Luo W, Kerr DJ. Effect of polyunsaturated fatty acids on the drug sensitivity of human tumour cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 1993; 67: 728-33.
112. Khan AL, Heys SD, Eremin O. Synthetic polyribonucleotides: current role and potential use in oncological practice. Eur J Surg Oncol 1995; 21: 224-7.
113. Wiltrout RH, Salup RR, Twilley TA, Yalmadge JE. Immunomodulation of natural killer activity by polyribonucleotides. Journal of Biological Response Modifiers 1985; 4: 512-17.
114. Braun W, Ishizuka M, Yajima Y et al. Spectrum and mode of actions of poly A:U in the stimulation of immune responses. In: Beers RF, Braun W, eds. Biological Effect of Polyribonucleotides. New York: Springer, 1971: 139.
115. Hovanessian AG, Youn JK, Buffet-Janvresse C et al. Enhancement of natural killer cell activity and 2-5A synthetase in operable breast cancer patients treated with polyadenylic-polyuridylic acid. Cancer 1985; 55: 357-62.
116. Donner M, Vaillier D, Lacour F. Changes in lymphocyte subpopulations in mice receiving a single injection of poly-A:U. Annual Review of Immunology 1977; 128: 1039-52.
117. Graziano KD, Levy CC, Schmukler M, Mardiney MR Jr. Parameters for effective use of synthetic double stranded polynucleotides in the amplification of immunologically induced lymphocyte tritiated thymidine incorporation. Cell Immunol 1974; 11: 47-56.
118. Morris CK, Johnson AG. Regulation of the immune system by synthetic polyribonucleotides VII. Suppression induced by pretreatment with poly A:U. Cell Immunol 1978; 39: 345-54.
119. Youn JK, Kim BS, Min JS et al. Adjuvant treatment of operable stomach cancer with polyadenylic-polyuridylic acid in addition to chemotherapeutic agents. Differential effect on natural killer cell and antibody-dependent cellular cytotoxicity. Int J Immunopharmacol 1987; 9: 313-24.
120. Khan AL, Richardson S, Broom J, Heys SD, Ah-See AK, Eremin O. Peri-operative acute phase response and cytokine release in women with breast cancer treated with polyadenylic-polyuridylic acid. Eur J Surg Oncol 1994; 20: 341 (Abstract).
121. Odean MJ, Trachte GJ, Johnson AG. Characterization of immune suppression induced by polyribonucleotides. Int J Immunopharmacol 1991; 13: 339-48.
122. Dy M, Arnould A, Schneider E. Poly(A)-poly(U) induces circulating colony-stimulating activity resulting from interactions between endogenous interleukin 6 and serum components. Exp Hematol 1991; 19: 261-6.
123. Youn JK, Kim BS, Min JS et al. Adjuvant treatment with chemotherapeutic agents and polyadenylic-polyuridylic acid in operable stomach cancers. I. Enhancement of natural killer cell activity. Yonsei Med J 1985; 26: 1-7.
124. Khan AL, Richardson S, Drew J et al. Polyadenylic-polyuridylic acid enhances the natural cell-mediated cytotoxicity in patients with breast cancer undergoing mastectomy. Surgery 1995; 118: 531-8.
125. Lacour J, Lacour F, Spira A et al. Adjuvant treatment with polyadenylic-polyuridylic acid (polyA.polyU) in operable breast cancer. Lancet 1980; ii: 161-4.
126. Lacour J, Lacour F, Spira A et al. Adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer: updated results of a randomised trial. BMJ 1984; 288: 589-92.
127. Lacour J, Laplanche A, Delozier T et al. Polyadenylic-polyuridylic acid plus locoregional and pelvic radiotherapy versus chemotherapy with CMF as adjuvants in operable breast cancer. Breast Cancer Res Treat 1991; 19: 15-22.
128. Youn JK, Kim BS, Min JS et al. Adjuvant treatment of operable stomach cancer with polyadenylic-polyuridylic acid in addition to chemotherapeutic agents: a preliminary report. Int J Immunopharmacol 1990; 12: 289-95.
129. Lacour J, Laplanche A, Malafosse M et al. Polyadenylic-polyuridylic acid as an adjuvant in resectable colorectal carcinoma: a 6 1/2 year follow-up analysis of a multicentric double blind randomized trial. Eur J Surg Oncol 1992; 18: 599-604.
130. Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80: 30-6.
131. Laurie JA, Moertel CG, Flemming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447-56.
132. Daly JM, Lieberman MD, Goldfine J et al. Enteral nutrition with supplemental arginine. RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery 1992; 112: 56-67.
133. Kemen M, Senkal M, Homann H-H et al. Early postoperative enteral nutrition with arginine-ω-3 fatty acids and ribonucleic acid-supplemented diet versus placebo in cancer patients: an immunologic evaluation of Impact. Crit Care Med 1995; 23: 652-9.
134. Daly JM, Weintraub FN, Shou J, Rosato EF, Lucia M. Enteral nutrition during multimodality therapy in upper gastrointestinal cancer patients. Ann Surg 1995; 221: 327-38.
135. Cerra FB, Lehman S, Konstantinides N, Konstantinides F, Shronts EP, Holman R. Effect of enteral nutrient on in vitro tests of immune function in ICU patients: a preliminary report. Nutrition 1990; 6: 84-7.